CO
COR.US Cencora Inc.
- Market cap
- USD 68.5B
- P/E
- 19.5x
- P/B
- 18.11x
- ROE
- 94.6%
- Dividend yield
- 0.76%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is COR.US undervalued?
Graham numberThe Graham number of Cencora Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cencora Inc. fundamental analysis
No fundamental analysis for Cencora Inc. yet.
Cencora Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and o…
Full company profileCencora Inc. financial statements
Cencora Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 153B | 168B | 180B | 190B | 214B | 239B | 262B | 294B | 321B | 337B |
| Gross Profit | 4.15B | 4.11B | 4.53B | 4.79B | 6.27B | 7.60B | 7.76B | 8.70B | 10.1B | 13.9B |
| Operating Income | 2.02B | 1.65B | 1.87B | 2.02B | 2.68B | 2.75B | 2.45B | 3.04B | 3.65B | 3.93B |
| EBITDA | 1.49B | 1.87B | 1.65B | -4.73B | 2.92B | 3.12B | 3.42B | 3.37B | 3.75B | 6.12B |
| Net Income | 414M | 1.66B | 855M | -3.40B | 1.54B | 1.70B | 1.75B | 1.51B | 1.55B | 3.48B |
| EPS | 1.87 | 7.53 | 4.04 | -17 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 | 18 |
| Balance Sheet | ||||||||||
| Total Assets | 35.3B | 37.7B | 39.2B | 44.3B | 57.3B | 56.6B | 62.6B | 67.1B | 76.6B | 87.1B |
| Total Liabilities | 33.3B | 35.0B | 36.5B | 45.1B | 56.8B | 56.5B | 61.9B | 66.3B | 74.8B | 83.4B |
| Shareholders' Equity | 2.06B | 2.93B | 2.88B | -1.02B | 223M | -212M | 522M | 646M | 1.51B | 3.68B |
| Cash & Short-term Investments | 2.44B | 2.49B | 3.37B | 4.60B | 2.55B | 3.53B | 2.69B | 3.23B | 4.39B | 4.88B |
| Total Debt | 3.79B | 4.66B | 4.49B | 4.98B | 8.75B | 7.59B | 6.82B | 6.65B | 9.33B | 11.3B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.49B | 1.41B | 2.34B | 2.21B | 2.67B | 2.70B | 3.91B | 3.48B | 3.88B | 4.79B |
| Capital Expenditure | 466M | 336M | 310M | 370M | 438M | 496M | 458M | 487M | 668M | 910M |
| Free Cash Flow | 1.02B | 1.07B | 2.03B | 1.84B | 2.23B | 2.21B | 3.45B | 3.00B | 3.21B | 3.88B |
| Ratios | ||||||||||
| ROE | 20.1% | 56.5% | 29.7% | - | 689.5% | - | 334.3% | 233.6% | 103.1% | 94.6% |
| ROA | 1.2% | 4.4% | 2.2% | -7.7% | 2.7% | 3.0% | 2.8% | 2.2% | 2.0% | 4.0% |
| Net Profit Margin | 0.3% | 1.0% | 0.5% | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% | 1.0% |
| Debt to Equity | 1.84x | 1.59x | 1.56x | - | 39.18x | - | 13.06x | 10.30x | 6.19x | 3.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cencora Inc. dividends
- Dividend yield
- 0.76%
- Forward dividend
- 2.64 USD
- Payout ratio
- 13.7%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 477M | 2.46 | 13.7% |
| 2025 | USD 437M | 2.24 | 28.1% |
| 2024 | USD 416M | 2.08 | 27.6% |
| 2023 | USD 399M | 1.95 | 22.8% |
| 2022 | USD 392M | 1.85 | 23.1% |
| 2021 | USD 367M | 1.76 | 23.8% |
| 2020 | USD 344M | 1.68 | - |
| 2019 | USD 339M | 1.60 | 39.6% |
| 2018 | USD 333M | 1.51 | 20.1% |
| 2017 | USD 320M | 1.45 | 77.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 16, 2009.
Who owns Cencora Inc.
- Insiders 4.31%
- Institutions 95.69%
- Public & others 0.00%
- Shares outstanding 191M
- Free float 180M
Top funds holding COR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.75M | 3.01% | -2.06% | Sep 2026 |
| Vanguard 500 Index Investor | 5.01M | 2.63% | -3.08% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 3.90M | 2.04% | -16.81% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 3.88M | 2.03% | -2.90% | Sep 2026 |
| Vanguard Health Care Inv | 2.61M | 1.37% | -8.28% | Sep 2026 |
| iShares Core S&P 500 ETF | 2.54M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 2.48M | 1.30% | -1.81% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 2.33M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 1.73M | 0.91% | -2.19% | Sep 2026 |
| Vanguard Wellington Inv | 1.54M | 0.81% | 0.00% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.40M | 0.73% | +0.88% | Oct 2026 |
| Fidelity Magellan | 1.23M | 0.65% | -0.75% | Sep 2026 |
| American Funds Invmt Co of Amer A | 1.15M | 0.60% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Value ETF | 1.13M | 0.59% | -5.41% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 1.08M | 0.57% | -1.97% | Sep 2026 |
| Vanguard Dividend Growth Inv | 1.06M | 0.55% | 0.00% | Sep 2026 |
| iShares Russell Mid-Cap Growth ETF | 1.05M | 0.55% | -0.07% | Oct 2026 |
| JHancock Disciplined Value Mid Cap I | 1.05M | 0.55% | -1.57% | Aug 2026 |
| Vanguard Institutional Index I | 1.01M | 0.53% | -2.93% | Sep 2026 |
| iShares MSCI USA Min Vol Factor ETF | 926K | 0.49% | +0.26% | Oct 2026 |
Top institutions holding COR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 18.2M | 9.54% | -8.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.4M | 6.49% | +0.53% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 9.61M | 5.04% | +0.22% | Jun 2026 |
| State Street Corp | 9.27M | 4.86% | +0.91% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 7.41M | 3.88% | +17.74% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 7.13M | 3.74% | -2.61% | Jun 2026 |
| JPMorgan Chase & Co | 5.94M | 3.11% | +21.66% | Jun 2026 |
| Geode Capital Management, LLC | 5.45M | 2.86% | -2.00% | Jun 2026 |
| Boston Partners Global Investors, Inc | 4.87M | 2.55% | +8.61% | Jun 2026 |
| Wellington Management Company LLP | 4.56M | 2.39% | +0.25% | Jun 2026 |
| FMR Inc | 4.12M | 2.16% | -38.35% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.09M | 2.14% | -9.83% | Jun 2026 |
| Bank of America Corp | 3.73M | 1.96% | -9.77% | Jun 2026 |
| NORGES BANK | 2.47M | 1.30% | +1.58% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.27M | 1.19% | +2.77% | Jun 2026 |
| Amundi | 2.23M | 1.17% | +43.53% | Jun 2026 |
| Northern Trust Corp | 2.16M | 1.13% | -1.09% | Jun 2026 |
| Amvescap Plc. | 2.02M | 1.06% | -49.31% | Jun 2026 |
| Capital Research Global Investors | 1.98M | 1.04% | +1.04% | Jun 2026 |
| Carmignac Gestion | 1.75M | 0.92% | +58.67% | Jun 2026 |
Cencora Inc. company profile
- Company name
- Cencora Inc.
- Ticker
- COR.US
- Exchange
- USA Stocks
- Listed since
- Apr 4, 1995
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 47,000
- Fiscal year end
- September
- Address
- 1 West First Avenue, Conshohocken, PA, United States, 19428-1800
- Phone
- 610 727 7000
- Website
- cencora.com
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Cencora Inc. management
10- Dr. Robert P. Mauch Ph.D., PharmDPresident, CEO & Director · born 1967
- Ms. Elizabeth S. Campbell J.D.Executive VP & Chief Legal Officer · born 1975
- Mr. James F. Cleary Jr.Advisor · born 1963
- Ms. Silvana BattagliaAdvisor · born 1968
- Ms. Eva C. BorattoExecutive VP & CFO · born 1967
- Mr. Lazarus KrikorianSenior VP, Chief Accounting Officer & Corporate Controller · born 1965
- Mr. Pawan Singh VermaExecutive VP and Chief Data & Information Officer · born 1977
- Mr. Bennett S. MurphySenior VP Of Investor Relations & Enterprise Productivity and Treasury
- Ms. Samantha L. HammockExecutive VP & Chief Human Resources Officer · born 1979
- Mr. Richard TremonteEVP and President of U.S. Pharmaceuticals & Animal Health